Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Butterfly Skin Therapy Pipeline Primed For Transformation

As Amryt's Oleogel-S10 Gets Priority Review

Executive Summary

No drugs are approved for epidermolysis bullosa and children with so-called butterfly skin are currently treated by cleaning open wounds and bandaging them. This could soon change.

You may also be interested in...



US FDA’s Botanical Drugs Guidance Will See Rare Outing For Amryt’s Filsuvez NDA

Amryt’s birch bark extract oleogel-S10 for Epidermolysis Bullosa patients might become only the third botanical drug to clear the FDA.

BI/Lilly's Jardiance Takes On AstraZeneca's Farxiga With Heart Failure Approval

Cardiologists in Europe who have so far been unwilling to embrace the SGLT2 class now have two drugs approved for heart failure with reduced ejection fraction, with Jardiance soon to join Farxiga on the market, potentially attractive options especially for their diabetic patients.

Orphazyme Tumbles Back To Earth As FDA Rejects Arimoclomol

Following a week of "insane trading" which saw the Danish stock soar based on social media chatter, US regulators have surprised the firm and investors by issuing a complete response letter for arimoclomol for Niemann-Pick disease type C.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144467

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel